Technical Analysis for KDNY - Chinook Therapeutics, Inc.

Grade Last Price % Change Price Change
D 16.49 7.01% 1.08
KDNY closed up 7.01 percent on Wednesday, February 24, 2021, on 54 percent of normal volume. The stock rose above its 50 day moving average, improving its intermediate-term outlook by crossing above that important trendline.

Trend Table & Recent EOD Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent Up Up Up
Historical KDNY trend table...

Date Alert Name Type % Chg
20 DMA Support Bullish 0.00%
Crossed Above 50 DMA Bullish 0.00%
Expansion Pivot Buy Setup Bullish Swing Setup 0.00%
Fell Below 50 DMA Bearish 7.01%
20 DMA Support Bullish 7.01%
Hammer Candlestick Bullish 7.01%
20 DMA Support Bullish 3.06%
Crossed Above 50 DMA Bullish 3.06%
MACD Bullish Centerline Cross Bullish 3.06%
50 DMA Resistance Bearish 6.32%
Older End-of-Day Signals for KDNY ...

   Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App

Alert Time
Up 1 ATR about 11 hours ago
Up 5% about 12 hours ago
50 DMA Resistance about 15 hours ago
Hammer Candlestick Entry about 15 hours ago
Rose Above Previous Day's High about 15 hours ago
View Earlier Intraday Alerts

Free Daily (Stock) Chart Reading

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

Chinook Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of precision medicines for kidney diseases. The company's lead program is atrasentan, an investigational Phase 3-ready endothelin receptor antagonist for the treatment of IgA nephropathy and other primary glomerular diseases. Its product candidates include BION-1301, an investigational anti-APRIL monoclonal antibody is being evaluated in a Phase 1b trial for IgA nephropathy; and CHK-336, a preclinical development candidate for an undisclosed ultra-orphan kidney disease, as well as research programs for other rare, severe chronic kidney diseases, including polycystic kidney disease. Chinook Therapeutics, Inc. is based in Seattle, Washington.
Classification

Sector: Healthcare
Industry: Biotechnology
Keywords: Biotechnology Clinical Medicine Clinical Development Monoclonal Antibody Kidney Disease Precision Medicine Chronic Kidney Disease Kidney Diseases Rare Chronic Kidney Diseases Iga Nephropathy

Is KDNY a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 21.68
52 Week Low 9.35
Average Volume 161,968
200-Day Moving Average 14.28
50-Day Moving Average 15.95
20-Day Moving Average 15.47
10-Day Moving Average 15.50
Average True Range 0.97
ADX 12.81
+DI 25.21
-DI 17.54
Chandelier Exit (Long, 3 ATRs ) 13.88
Chandelier Exit (Short, 3 ATRs ) 16.95
Upper Bollinger Band 16.75
Lower Bollinger Band 14.19
Percent B (%b) 0.9
BandWidth 16.56
MACD Line 0.08
MACD Signal Line 0.00
MACD Histogram 0.0872
Fundamentals Value
Market Cap 695.19 Million
Num Shares 42.2 Million
EPS
Price-to-Sales 0.00
Price-to-Book 0.00
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 18.19
Resistance 3 (R3) 18.00 17.25 17.90
Resistance 2 (R2) 17.25 16.82 17.34 17.81
Resistance 1 (R1) 16.87 16.55 17.06 17.06 17.71
Pivot Point 16.12 16.12 16.22 16.21 16.12
Support 1 (S1) 15.74 15.69 15.93 15.93 15.27
Support 2 (S2) 14.99 15.42 15.08 15.17
Support 3 (S3) 14.61 14.99 15.08
Support 4 (S4) 14.80